Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
16 hedge funds and large institutions have $844K invested in Argos Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 16 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
85% more capital invested
Capital invested by funds: $456K → $844K (+$388K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
43% less funds holding
Funds holding: 28 → 16 (-12)
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Pharmstandard International
Luxembourg
|
+$316K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$66.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$47.8K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$28.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$157K |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$96K |
| 3 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$24K |
| 4 |
KeyBank National Association
Cleveland,
Ohio
|
-$18K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4 | -2 | -3% |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2 | -1 | -50% |
|
28
Barclays
London,
United Kingdom
| – | +$2 | +1 | New |
|
29
BlackRock
New York
| – | +$4 | +2 | +0.5% |
|
30
Bank of America
Charlotte,
North Carolina
| – | +$549 | +293 | New |
|
ARGS Hedge Fund Activity: Q1 2018 in Review
16 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q1 2018, worth a combined $844K — up 85% from $456K a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ARGS and 4 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Pharmstandard International, adding an estimated $316K. The largest seller was Vanguard Group, exiting entirely with an estimated $157K sold.
- 16 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q1 2018, down from 28 in Q4 2017.
- Funds reported $844K of Argos Therapeutics, Inc. stock for Q1 2018, up 85% quarter-over-quarter.
- 4 funds opened new Argos Therapeutics, Inc. positions in Q1 2018 and 16 closed out, a net change of -12 holders.
- The largest Argos Therapeutics, Inc. buyer in Q1 2018 was Pharmstandard International, an estimated $316K added.
- The largest Argos Therapeutics, Inc. seller in Q1 2018 was Vanguard Group, an estimated $157K sold.
Based on aggregated 13F filings for Q1 2018.